Of Life and Limb: Addition of Low-Dose Rivaroxaban for Secondary Prevention After Peripheral Artery Disease Surgery

Circulation. 2021 Oct 5;144(14):1117-1119. doi: 10.1161/CIRCULATIONAHA.121.056291. Epub 2021 Oct 4.

Authors

Elizabeth L George¹, Shipra Arya^{1

2}

Affiliations

¹ Division of Vascular Surgery, Department of Surgery, Stanford University School of Medicine, CA (E.L.G., S.A.).
² Surgery Service Line, VA Palo Alto Healthcare System, CA (S.A.).

PMID: 34606303
DOI: 10.1161/CIRCULATIONAHA.121.056291

No abstract available

Keywords: Editorials; peripheral artery disease; rivaroxaban.

Publication types

Editorial
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Factor Xa Inhibitors / adverse effects
Humans
Peripheral Arterial Disease*
Rivaroxaban* / adverse effects
Secondary Prevention

Substances

Factor Xa Inhibitors
Rivaroxaban